mercredi 13 novembre 2019

Onco Actu du 13 novembre 2019


1. BIOLOGIE



Colorectal Cancer Study Reveals Gut Microbe, Methylation Shifts [Genome Web]











Protein could offer therapeutic target for pancreatic cancer [The Francis Crick Institute]











1.4 BIOLOGIE - TECHNOS, MODÈLES



CRISPR: the movie [Nature]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Former FDA commissioner calls for a full ban on pod-based e-cigarettes [STAT]











UK teenager needed life support over vaping-linked disease [The Guardian]











Facing ‘Certain Death,’ Teenager With Vaping Injury Gets Double Lung Transplant [NY Times]











Michigan boy, 17, gets double lung transplant after damage from vaping [Reuters]











CDC and Anti-E-Cigarette Researcher Still Clinging to Faint Hope that Traditional E-Cigarettes are Causing Outbreak [The Rest of the Story]










3.6 PRÉVENTION - ACTIVITÉ PHYSIQUE



Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz [NCI]










4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Deep Learning Assists in Detecting Malignant Lung Cancers [RSNA]











5. TRAITEMENTS



Mount Sinai Researcher’s Examine the Metabolic Effects of an Oral Blood Cancer Drug [Mount Sinai]











5.10 TRAITEMENTS - ESSAIS



Basic Research Spurs New Wave of Clinical Trials of Therapies for T-Cell Lymphoma [Dana-Farber Cancer Institute]











5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases [Editas]











Editas and Celgene sub Juno are tackling hottest immunotherapy cells [EndPoints]











5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



Kiadis abandons lead PhIII program, shifts focus to natural killer cells [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Merck shutters French research site in a reorganization aimed at eliminating more than 200 jobs [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma [Exelixis]











6.1 OBSERVATION



Heart disease and cancer risk may be linked [AHA]










6.7 DMP, BIG DATA & APPLIS



Google’s ‘Project Nightingale’ Secretly Gathers Personal Health Data on Millions of Americans - Time to Refuse Use Of EMR's In Your Healthcare? [Health Care Renewal]